| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3084821 | Pediatric Neurology | 2014 | 8 Pages |
Abstract
This study demonstrated 95% efficacy, including 42% seizure-free patients and the favorable tolerability of desensitization to oxcarbazepine in patients with intractable epilepsy and one patient with paroxysmal kinesigenic dyskinesia. Screening for sensitive human leukocyte antigen types and exclusion of severe hypersensitivity reactions should precede desensitization.
Related Topics
Life Sciences
Neuroscience
Developmental Neuroscience
Authors
Bolyun MD, Hee Joon MD, Eun-Suk MD, PhD, Munhyang MD, PhD, Jeehun MD, PhD,